Affordable Access

deepdyve-link
Publisher Website

[New immunotherapeutic approaches in oncology and hematology].

Authors
  • Kroemer, M1
  • Turco, C2
  • Galaine, J3
  • Deschamps, M3
  • Limat, S4
  • Borg, C5
  • 1 Service pharmacie, CHRU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France; Inserm, unité mixte de recherche 1098, université de Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France. Electronic address: [email protected] , (France)
  • 2 Inserm, unité mixte de recherche 1098, université de Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France; Service d'oncologie médicale, CHRU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France; Service de chirurgie digestive et de transplantation hépatique, CHRU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France. , (France)
  • 3 Inserm, unité mixte de recherche 1098, université de Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France. , (France)
  • 4 Service pharmacie, CHRU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France; Inserm, unité mixte de recherche 1098, université de Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France. , (France)
  • 5 Inserm, unité mixte de recherche 1098, université de Franche-Comté, 8, rue du Docteur Jean-François-Xavier-Girod, 25000 Besançon, France; Service d'oncologie médicale, CHRU de Besançon, 3, boulevard Alexandre-Fleming, 25000 Besançon, France. , (France)
Type
Published Article
Journal
Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
Publication Date
Aug 01, 2015
Volume
22
Issue
3
Pages
132–140
Identifiers
DOI: 10.1016/j.tracli.2015.05.002
PMID: 26068883
Source
Medline
Keywords
Language
French
License
Unknown

Abstract

Scientific advances in the last decade have demonstrated the critical role of host immune system in the elimination and suppression of cancer cells. Better knowledge of signaling pathways has enabled the development of new cancer immunotherapy. The discovery of negative feedback mechanisms following the lymphocyte activation has promoted the development of new antibodies targeting molecule inhibitors such as PD1, PDL1 or CTLA-4. Dramatic results were obtained with melanoma. Checkpoint inhibitors (pembrolizumab and ipilimumab) have many advantages in terms of rate of objective response and overall survival. Recent studies in translational research aimed to understand and analyze mechanisms of action of anti-PD1/anti-PDL1. Expression of PDL1 in the tumor is associated with a significantly greater objective response rate (immunohistochemistry). Nevertheless, limits with tumor immunohistochemical analysis encourage new biomarkers research. Other immunotherapy approaches, such as cell and gene therapies using engineered T cells call for further advancements to broaden their applicability. However, these therapies are very expensive and their manufacturing process very restrictive, which could lately limit their use in case of inefficiency of checkpoint inhibitors or when lymphocytic infiltration in tumor is absent. In this case, the objective would be to engineer ex vivo the patient's immune system by restoring the ability of T cells to identify and suppress tumor cells. Currently, two gene-reprogramming tools are under development: chimeric antigen receptor and TCR modified T cells. Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Report this publication

Statistics

Seen <100 times